Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Racemethionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.59 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methionine SCHEMBL1955009 | 1.00 | BHMT (0.59) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Methionine SCHEMBL108277 | 1.00 | BHMT (0.59) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Racemethionine SCHEMBL8954847 | 0.98 | BHMT (0.57) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Methionine SCHEMBL8954852 | 0.98 | BHMT (0.57) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Racemethionine SCHEMBL29016958 | 0.95 | BHMT (0.54) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Methionine SCHEMBL17847432 | 0.95 | BHMT (0.58) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Racemethionine SCHEMBL17847431 | 0.95 | BHMT (0.58) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Glutamic Acid SCHEMBL12276999 | 0.93 | GRM8 (0.60) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Leucine SCHEMBL28072785 | 0.92 | SLC7A5 (0.58) | BHMTBHMT2RNPEPGRM8GRM6 | |
| Leucine SCHEMBL10439303 | 0.92 | SLC7A5 (0.58) | BHMTBHMT2RNPEPGRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257541-B1 | POLYPHARMACOPHORIC AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2008-09-03 | — | — | EP | claimed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11555061-B2 | Albumin variants and conjugates | ALBUMEDIX, LTD (GB) | 2023-01-17 | — | — | US | disclosed |
| US-20200392206-A1 | ALBUMIN VARIANTS AND CONJUGATES | SARTORIUS ALBUMEDIX LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| EP-3061817-B1 | ALKALINE PROTEASE VARIANTS | KAO CORP (JP) | 2018-12-12 | — | — | EP | disclosed |
| EP-3243835-A1 | ALBUMIN VARIANTS AND CONJUGATES | Albumedix A/S (DK) | 2017-11-15 | — | — | EP | disclosed |
| EP-2396347-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX AS (DK) | 2017-04-12 | — | — | EP | disclosed |
| US-20170081389-A1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2017-03-23 | — | — | US | disclosed |
| US-9493545-B2 | Albumin variants and conjugates | ALBUMEDIX A/S (DK) | 2016-11-15 | — | — | US | disclosed |
| EP-3061817-A1 | ALKALINE PROTEASE VARIANTS | KAO CORPORATION (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-1017275-B1 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | MURPHY MICHAEL A (US) | 2009-11-25 | — | — | EP | disclosed |
| CN-1216599-C | Polyamine treatment of neurological disorders | MURPHY MICHAEL A (US) | 2005-08-31 | — | — | CN | disclosed |
| US-6809078-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE USE IN THE GENERATION OF INSECT RESISTANT PLANTS; BIOLOGICAL PEST CONTROL | MONSANTO TECHNOLOGY LLC | 2004-10-26 | — | — | US | disclosed |
| US-6576672-B1 | Parkingson's Disease and dementias characterized by mito-chondrial damage; such as 3,7-diazanonane-1,9-diamine; neutralizing dopamine depriving effect | MURPHY MICHAEL A (US) | 2003-06-10 | — | — | US | disclosed |
| US-20030101482-A1 | Compositions encoding lepidopteran-toxic polypeptides and methods of use | MONSANTO TECHNOLOGY LLC | 2003-05-29 | — | — | US | disclosed |
| EP-1017275-A4 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | MURPHY MICHAEL A (US) | 2002-12-18 | — | — | EP | disclosed |
| CN-1271250-A | Polyamine treatment of neurological disorders | MICHAEL A MURPHY (US) | 2000-10-25 | — | — | CN | disclosed |
| EP-1017275-A1 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | Murphy, Michael A. (US) | 2000-07-12 | — | — | EP | disclosed |
| US-5906996-A | Tetramine treatment of neurological disorders | MURPHY MICHAEL A (US) | 1999-05-25 | — | — | US | disclosed |
| WO-1999008519-A1 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | MURPHY MICHAEL A (US) | 1999-02-25 | — | — | WO | disclosed |